Recent Advances in Healthcare Diagnostics and Therapies

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts new life sciences trends across diagnostics and therapeutics. Clinical trial results for several indications using antibody therapy are illustrated. Innovations in engineered 3D heart tissue and metabolome analyses for drug testing are also depicted. The corresponding clinical trial scenario is exhibited, along with the corresponding industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applicati

Table of Contents

Recent Advances in Healthcare Diagnostics and TherapiesInnovations in Healthcare Diagnostics and TherapeuticsEncouraging Phase III Results for Eli Lilly's Antibody Therapy for MigraineEngineering 3D Heart Tissue for Enabling Effective Drug TestingEnabling Comprehensive Analysis of the MetabolomeEnhanced Clinical Decisions through Comprehensive DiagnosticsClinical Trial Analysis and Industry InteractionsClinical Trial AnalysisIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.